Core Viewpoint - The company Changjie Tong (01588.HK) announced that its controlling shareholder, Yongyou Network Technology Co., Ltd. (stock code: 600588), will sell a total of 42,107,849 H-shares through block trading, which represents approximately 12.93% of the company's issued shares as of the announcement date [1] Summary by Relevant Sections - **Share Sale Details** - Yongyou and its subsidiary, Yongyou Youpu Information Technology Co., Ltd., will sell 28,135,071 shares and 13,972,778 shares respectively, at a price of HKD 7.60 per share [1] - The shares sold represent about 8.64% and 4.29% of the company's issued shares, excluding treasury shares [1] - **Post-Sale Ownership** - After the sale, Yongyou will continue to hold 174,350,542 shares in the company, which accounts for approximately 53.53% of the issued shares [1] - This includes 173,344,366 shares directly held by Yongyou and 1,006,176 shares held by its subsidiary, Beijing Yongyou Happiness Investment Management Co., Ltd. [1] - **Strategic Implications** - The controlling shareholder expresses confidence in the company's business operations [1] - The sale is intended to deepen connections with long-term value investors, broaden the shareholder base, and enhance the liquidity of the company's stock [1]

Group 1 - The stock price of Boji Pharmaceutical closed at 11.98 yuan on August 21, 2025, down 3.07% from the previous trading day, with a trading volume of 567 million yuan and a turnover rate of 16.61% [1] - Boji Pharmaceutical operates in the healthcare services industry, with 99.39% of its revenue coming from service-related activities as reported in the 2024 financial report [1] - The controlling shareholder Wang Tingchun and his concerted parties plan to reduce their holdings by no more than 11.4865 million shares, accounting for 3% of the total share capital, due to personal funding needs [1] Group 2 - On August 21, the net outflow of main funds was 18.1492 million yuan, but over the past five days, the overall net inflow of main funds was 139 million yuan [1]

步科股份(688160.SH)发布公告，公司于近日收到控股股东上海步进出具的《关于减持股份计划的告知 函》，因股东自身资金需求，控股股东上海步进计划通过集中竞价及大宗交易方式减持其所持有的公司 股份合计不超过272.5万股(不超过公司总股本的3%)。 ...

Group 1 - The controlling shareholder, Hong Kong Junyao, reduced its stake in the company by 17.505 million shares, accounting for 1.5% of the total share capital [1] - The reduction took place between June 27, 2025, and July 4, 2025, through block trading [1] - The share price during the reduction ranged from 48.55 yuan to 51.19 yuan per share [1] Group 2 - After the completion of the reduction, Hong Kong Junyao and its concerted party, Zhongshan Hongting, hold a combined shareholding of 85.98%, down from 87.48% [1] - The change in shareholding percentage reached 1% [1]

Group 1 - The controlling shareholder Chengdu Local Construction Machinery Engineering Co., Ltd. and its concerted parties have reduced their shareholding in Huason Pharmaceutical Co., Ltd. from 70.00% to 68.76% through various trading methods [1][2] - A total of 5,193,650 shares were reduced, representing a decrease of 1.24% of the company's total share capital [1][2] - The shareholding structure post-reduction shows that Chengdu Local Construction and its concerted parties now hold 287,123,875 shares [1][2] Group 2 - The reduction of shares was executed in compliance with previously disclosed plans, and the total number of shares reduced is within the limits set by the reduction plan [2][3] - The reduction occurred between January 24, 2025, and June 9, 2025, with specific details on the number of shares sold through block trades and centralized bidding [1][2] - The announcement confirms that the information provided is accurate and complete, with no misleading statements or significant omissions [1]

Core Viewpoint - The controlling shareholder and actual controller of Yiming Pharmaceutical, Gao Fan, is planning to change the company's control, leading to a temporary suspension of the company's stock trading due to significant uncertainty surrounding the matter [1][3]. Group 1: Shareholder Information - Gao Fan, the founder of Yiming Pharmaceutical, holds 48.80 million shares, accounting for 25.59% of the total share capital, making him the largest shareholder [3]. - In September 2021, Gao Fan stepped down from his positions as chairman and general manager of the company but continued to hold a position in a subsidiary [3]. - Following his resignation, Gao Fan initiated a share reduction plan in June 2022, intending to reduce his holdings by up to 9.56 million shares (5% of total shares), but only reduced 635,800 shares (0.33%) by the end of the plan [4]. Group 2: Financial Performance - Yiming Pharmaceutical's revenue from 2020 to 2024 was as follows: 602.62 million, 725.46 million, 856.73 million, 667.04 million, and 651.88 million yuan, respectively, with net profits of 41.09 million, 43.47 million, 46.12 million, 15.73 million, and 47.46 million yuan [7]. - In 2023, the company experienced a 22.14% decline in revenue and a significant 65.9% drop in net profit [7]. - The company attributed the poor performance to changes in market conditions, industry environment, and underperformance of third-party cooperative products [8]. Group 3: Strategic Moves - Yiming Pharmaceutical had previously announced a private placement plan in April 2021, intending to raise between 200 million and 350 million yuan, but the plan was terminated four months later due to market conditions and business development considerations [6]. - The company acquired a 51% stake in Inner Mongolia Bostai Enterprise Management Service Co., Ltd. for 30.6 million yuan in August 2021, but the acquisition faced criticism due to the high premium paid [8].